A Phase 2 Study to Explore the Efficacy and Safety of HB0017 Longer Dose Interval in Psoriasis Patients
- First Posted Date
- 2024-09-12
- Last Posted Date
- 2024-09-12
- Lead Sponsor
- Huabo Biopharm Co., Ltd.
- Target Recruit Count
- 200
- Registration Number
- NCT06592274
- Locations
- 🇨🇳
Shandong First Medical University Affiliated Dermatology Hospital, Jinan, Shandong, China
Study of Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2024-06-27
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Huabo Biopharm Co., Ltd.
- Target Recruit Count
- 400
- Registration Number
- NCT06477237
- Locations
- 🇨🇳
The Second Hospital of Shanxi Medical University, Taiyuan, China
🇨🇳Wenzhou Medical University Affiliated First Hospital, Wenzhou, China
🇨🇳The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
A Study of HB0025 Injection in Patients With Advanced Renal Cancer
- First Posted Date
- 2024-01-24
- Last Posted Date
- 2024-01-24
- Lead Sponsor
- Huabo Biopharm Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT06222125
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Study of HB0030 Injection in Patients With Advanced Solid Tumors
- First Posted Date
- 2023-01-31
- Last Posted Date
- 2023-01-31
- Lead Sponsor
- Huabo Biopharm Co., Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT05706207
- Locations
- 🇨🇳
the First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
A Study to Evaluate the Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis
- First Posted Date
- 2022-09-08
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Huabo Biopharm Co., Ltd.
- Target Recruit Count
- 160
- Registration Number
- NCT05531682
- Locations
- 🇨🇳
The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, China
🇨🇳Dermatology Hospital of Jiangxi Province, Nanchang, Jiangxi, China
A Study of HB0017 in Patients With Moderate to Severe Plaque Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2022-07-05
- Last Posted Date
- 2022-07-07
- Lead Sponsor
- Huabo Biopharm Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT05442788
- Locations
- 🇨🇳
The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
A Study of of HOT1030 in Patients With Advanced Solid Tumors
- First Posted Date
- 2021-09-29
- Last Posted Date
- 2021-09-29
- Lead Sponsor
- Huabo Biopharm Co., Ltd.
- Target Recruit Count
- 42
- Registration Number
- NCT05060263
- Locations
- 🇨🇳
Shanghai Huaota Biopharmaceutical Co., Ltd., Shanghai, Shanghai, China
A Study of HB002.1T Plus Chemotherapy in Subjects With Solid Tumor
- First Posted Date
- 2021-03-17
- Last Posted Date
- 2021-07-28
- Lead Sponsor
- Huabo Biopharm Co., Ltd.
- Target Recruit Count
- 72
- Registration Number
- NCT04802980
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China
A Study of Injection HB0025 in Patients With Advanced Solid Tumors
- First Posted Date
- 2020-12-22
- Last Posted Date
- 2022-06-01
- Lead Sponsor
- Huabo Biopharm Co., Ltd.
- Target Recruit Count
- 154
- Registration Number
- NCT04678908
- Locations
- 🇨🇳
The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
🇨🇳Central Hospital Affiliated to ShanDong First Medical University, Jinan, Shandong, China
A Study of Injection HB0017 in Adult Healthy Volunteers
- First Posted Date
- 2020-08-07
- Last Posted Date
- 2021-07-28
- Lead Sponsor
- Huabo Biopharm Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT04505033
- Locations
- 🇳🇿
Auckland Clinical Studies Ltd, Grafton, Auckland, New Zealand